Is Gennex Lab. overvalued or undervalued?

As of 2 June 2025, Gennex Lab. has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 17.62, an EV to EBITDA of 9.98, and a PEG ratio of 0.58, indicating strong growth potential relative to its price. In comparison to its peers, Gennex Lab. has a similar PE ratio to the industry average, while its EV to EBITDA is competitive, suggesting it is well-positioned within the Pharmaceuticals & Biotechnology sector. Notably, its ROCE stands at 16.09%, which is indicative of efficient capital utilization. Despite recent underperformance compared to the Sensex on a year-to-date basis, the long-term returns over 5 and 10 years highlight the company's strong growth trajectory.